A prospective observational safety study of patients with BRAFV 600 -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study).

Philippa CorrieP TerheydenA J Ten TijeR HerbstR JansenM MarplesD DebusR MarconciniM Blasinska-MorawiecK FreivogelM L G MunsonG R GoodmanJ J HsuN SadetskyD ColburnP Rutkowski

Published in: The British journal of dermatology (2019)

Keyphrases

newly diagnosed